European Psychiatry - Volume 41 - April 2017

278 / 916

S274 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302
Methods A total of 984 patients meeting the DSM-IV criteria for
schizophrenia who switched their antipsychotics to be paliperi-
done ER were recruited from 61 sites in five countries in Southeast
Asia. We assessed patients in terms of demographic profile, sleep
quality and daytime drowsiness as visual analog scale.
Results Patients in our studies received paliperidone ER treat-
ment for 6 months. About 70% completed the treatment. Sleep
quality and also daytime drowsiness were significantly increased in
patients compared with their baseline. The predictive factors that
have effect on sleep profile improvement were completion of the
study and baseline PANSS score.
Conclusion Patients receiving paliperidone ER were found to
have improvement in sleep quality and also improvement in day-
time drowsiness, especially in patients within completion group
and the higher baseline PANSS score.
Disclosure of interest The author has not supplied his/her decla-
ration of competing interest.
EW0493
Measuring motivation in patients
with schizophrenia with apathy
evaluation Scale (AES). Pilot study of
the Russian version
M. Minyaycheva ∗, K. Kiselnikova , L. Movina , I. Gladyshev ,
O. Papsuev
Moscow Research Institute of Psychiatry, Outpatient psychiatry and
organization of psychiatric care, Moscow, Russia
∗ Corresponding author.
Introduction Reduction of mental productivity and motivation in
patients with schizophrenia is one of the core features of negative
symptoms of schizophrenia spectrum disorders. Lack of motiva-
tion affects social functioning and outcomes, reduces effects of
psychosocial treatment and rehabilitation.
Objectives To research AES abilities in measuring motivation in
patients with schizophrenia spectrum disorders. The aim of the
study was to investigate correlations of Russian translation of
clinician-rated and self-rated versions with PANSS amotivation
subscale and negative subscale items.
Methods Fifty patients with schizophrenia spectrum disorders
were recruited to participate in the study and were assessed with
PANSS, AES-C and AES-S by trained raters. Only patients in “sta-
bilized” state that met inclusion criteria of PANSS total score ≤ 80
points were eligible for consecutive AES assessment.
Results Overall, moderate positive correlations were established
between AES-C and PANSS amotivation subscale N2 and N4 items,
N6 item and total PANSS negative subscale. No significant correla-
tions with G16 itemwere registered. AES-C and AES-S versions also
showed positive Spearman correlations (r = 0.43; P < 0.05), while
no correlations between AES-S and amotivation PANSS items were
registered.
Discussion Moderately strong correlations between AES-C and
PANSS N2, N4 and N6 items show feasibility of AES-C version
in terms of measuring motivation in patients with schizophrenia
spectrum disorders. Results of AES-S analysis demonstrate certain
problems in patients’ abilities in self-assessingmotivation. Patients
with prevailing paranoid syndrome showed poorer results in AES-S
scores.
Conclusions AES-C is a sensitive psychometric tool with good
properties in measuring amotivation in patients with schizophre-
nia.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0494
Efficacy and quality of life in patients
with schizophrenia and
schizoaffective disorders treated with
long-acting paliperidone palmitate:
A naturalistic longitudinal study
A. Nivoli ∗, L. Folini , L. Floris , M. Antonioli , F. Pinna ,
M. Paolo , C. Bernardo , L. liliana
1 University of Sassari, Department of Psychiatry, Sassari, Italy
2 University of Cagliari, Department of Psychiatry, Cagliari, Italy
∗ Corresponding author.
Introduction Intramuscular paliperidone palmitate (PP) is a long-
acting, atypical antipsychotic for ntramuscular (IM) administration
in the treatment of patients with schizophrenia.
Objective To study efficacy and quality of life in patients with
schizophrenia and schizoaffective disorders treated with long-
acting paliperidone palmitate.
Method A non-randomized, prospective naturalistic study was
performed in out-patients with schizophrenia and schizoaffective
disorder unsuccessfully treated with oral antipsychotics. Efficacy
of PP over time was evaluated by using BPRS 24-items (Brief Psy-
chiatric Rating Scale) Quality of life was evaluated by the QL-Index
(Quality of life Index) at T0 and at most recent visit (T1).
Results Data were available for 16 outpatients consecutively
prescribed PP and naturalistically treated attending at the Psy-
chiatric Clinic, University of Sassari. Patients were predominantly
male (n = 9; 56.2%), with schizophenia (n = 10; 62.5%). Three
patients dropped out (18.8%). Mean time on PP treatment was
870.0 days (sd 217.02) at a mean PP maintenance dose of
97.82± 37.17mg eq. BPRS mean total score at T0 was 55 (sd
14.5) and at T1 was 44.8 (sd 11.8). Ql-Index mean total score
was 5 (sd 1.6) at T0 and 7.2 (sd 2.4) at T1. Paired sample test
showed a statistically significant difference in deacreasing symp-
toms at BPRS over time (P = 0.009) and in improving Quality
of life at QL-Index (P = 0.017). The analyses showed a signif-
icant improving at the following BPRS sub-items: Depression
(P = 0.021), Hostility (P = 0.022), Suspiciousness (P= 0.005), Halluci-
nations ( P = 0.050), Unusual thought content (P = 0.029), Self-neglet
(P = 0.028), Conceptual disorganization (P = 0.044), Emotional with-
drawal ( P= 0.028) and Distractibility (P = 0.014).
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0495
A randomized single-blind placebo
controlled trial of memantine, as
addjunctive therapy for treatment of
negative symptoms of paranoid
schizophrenia
Y. Osadshiy ∗, D. Archakov , E. Tarakanova
The Volgograd Scientific-Production Association “YugMed”,
Psychiatry and Addiction, Volgograd, Russia
∗ Corresponding author.
This study analyses the efficiency of memantine–an antagonist
of N-methyl-d -aspartate receptors–as adjunctive therapy for the
treatment of negative symptoms of paranoid schizophrenia. Fifty-
two patients (30 males; age 20–50 years) were included with the
diagnosis of F20.014 and F20.024 according to the international
classification of diseases (version 10). The patients had been receiv-
ing neuroleptic monotherapy with a fixed dose for a period of
at least 4 weeks prior to randomization. Clinical data were col-
lected 8 weeks after memantine had been introduced as part of
the treatment regimen. A patient was considered as responding to
treatment if they: